Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...
Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...
Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback